Grzegorz S Nowakowski

Oct 17, 2024 | onclive.com | Grzegorz S Nowakowski

CommentaryVideoOctober 17, 2024Author(s):Grzegorz S. Nowakowski, MD, discusses the clinical implications of the FDA approval of third-line epcoritamab for relapsed/refractory follicular lymphoma. Grzegorz S.

Sep 13, 2024 | onclive.com | Grzegorz S Nowakowski

CommentaryVideoSeptember 13, 2024Author(s):Grzegorz S. Nowakowski, MD, discusses unmet needs that remain to be addressed in patients with relapsed/refractory follicular lymphoma. Grzegorz S. Nowakowski, MD, consultant, Division of Hematology; enterprise deputy director, Clinical Research, Mayo Clinic Comprehensive Cancer Center, discusses unmet needs to be addressed in the treatment of patients with relapsed/refractory follicular lymphoma.

Sep 6, 2024 | onclive.com | Grzegorz S Nowakowski

Grzegorz S. Nowakowski, MD, consultant, Division of Hematology; enterprise deputy director, Clinical Research, Mayo Clinic Comprehensive Cancer Center, discusses the current treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), emphasizing the need for novel therapeutic approaches to treat patients in the second-line setting.

Sep 4, 2024 | onclive.com | Grzegorz S Nowakowski

CommentaryVideoSeptember 4, 2024Author(s):Grzegorz S. Nowakowski, MD, discusses results from the EPCORE NHL-1 trial of third-line epcoritamab in relapsed/refractory follicular lymphoma. Grzegorz S.

Jul 17, 2024 | onclive.com | Grzegorz S Nowakowski

Grzegorz S. Nowakowski, MD, consultant, Division of Hematology; enterprise deputy director, Clinical Research, Mayo Clinic Comprehensive Cancer Center, discusses the significance of the FDA approval of epcoritamab-bysp (Epkinly) as a third-line treatment option in relapsed/refractory follicular lymphoma. On June 16, 2024, the FDA approved this bispecific antibody for patients with relapsed/refractory follicular lymphoma following 2 or more lines of systemic therapy.